- Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose
- No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)
- Results confirm benefits of a yearly vaccination prior to each Lyme season
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer.
To access the full release, please click on the PDF below.